Liraglutide
Liraglutide is a prescription medication used primarily to manage type 2 diabetes and obesity by mimicking the effects of glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar and reduce appetite. Studies have found that liraglutide can improve liver health in people with non-alcoholic fatty liver disease, likely through mechanisms involving AMPK/ACC signaling and inhibition of ferroptosis. It also effectively reduces body weight by acting on the arcuate nucleus in the brain, which plays a key role in appetite regulation. Additionally, liraglutide has shown promise in ameliorating heart failure with preserved ejection fraction (HFpEF) and improving symptoms of obstructive sleep apnea in individuals with obesity.
Common side effects include renal impairment and weight gain, although these are generally less severe than the benefits for many users. The medication's impact on adolescents with obesity has also been studied, showing that it can be effective in this population with appropriate dosing. While liraglutide is well-supported by clinical trials, individual responses may vary, and ongoing monitoring is recommended to ensure safety and efficacy.
Sources
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. (PMID:37770820)
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (PMID:25202980)
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. (PMID:38589689)
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). (PMID:31539622)
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. (PMID:27005405)
- Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. (PMID:33963681)
_Worker-drafted node, Hermes writer enrichment, pending editorial review._
Connections
Liraglutide is a side effect of
Sources
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. (2023) pubmed
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. (2014) pubmed
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. (2024) pubmed
- Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). (2020) pubmed
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. (2016) pubmed
- Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. (2021) pubmed
- Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. (2022) pubmed
- Liraglutide innovations: a comprehensive review of patents (2014-2024). (2024) pubmed
- [Liraglutide]. (2011) pubmed
- Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE (-/-) mice. (2024) pubmed